Brought to you by 
ContraVir buys fellow antivirals developer Ciclofilin
14 Sep 2020
Executive Summary
Expanding its hepatitis B pipeline, ContraVir Pharmaceuticals Inc. is acquiring fellow antivirals developer Ciclofilin Pharmaceuticals Inc. (developing cyclophilin inhibitors) in exchange for the right to receive future earn-out payments in the form of up to $17mm in cash and up to 10% of ContraVir's issued and outstanding common stock.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ContraVir buys fellow antivirals developer Ciclofilin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice